Owen Witte, MD, is recognized for multiple seminal contributions over the past 50 years impacting our understanding of human leukemias, immune disorders, and epithelial cancers, which have defined new ...

Cure rates are excellent in classical Hodgkin lymphoma. The challenge is tailoring the treatment to the individual patient to avoid not only overtreatment and treatment-related sequelae but also ...

In recent years, there has been a headlong rush into the use of prostate-specific membrane antigen (PSMA)–targeted PET for the staging and restaging of men with prostate cancer (PC). To date, there ...

Nectin-4 is an overexpressed biomarker in 60%–70% of triple-negative breast cancer (TNBC) cases and an ideal target for radiotherapy and PET imaging. In this study, theranostic radioimmunoconjugates ...

Despite well-documented limitations, current guidelines recommend the use of size-based RECIST 1.1 for response assessment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) under ...

AB001, a prostate-specific membrane antigen (PSMA)–targeted small molecule labeled with the in vivo–generating α-emitter 212Pb, was investigated in a phase 0 trial in patients with metastatic ...

Pilot Study of Nectin-4–Targeted PET Imaging Agent 68 Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human ...

Given the variability in the effectiveness of immune checkpoint blocking therapy among patients and tumor types, development of noninvasive methods for longitudinal assessment of immune cell function ...

The diagnosis and surveillance of clear cell renal cell carcinoma (ccRCC) remains a clinical challenge. The high and specific expression of the cluster of differentiation 70 (CD70) in ccRCC makes it a ...

Identifying cancer therapy resistance is a key time-saving tool for physicians. Part of chemotherapy resistance includes senescence, a persistent state without cell division or cell death. Chemically ...